Ipsilateral Lymphadenopathy After COVID-19 Vaccination in Patients With Newly Diagnosed Breast Cancer

• Published in: Journal of breast cancer Vol. 25; no. 2; pp. 131 - 139
• Main Authors: Ha, Su Min, Cheun, Jong-Ho, Lee, Su Hyun, Kim, Soo-Yeon, Park, Ah Reum, Kim, Yeon Soo, Yoen, Heera, Lee, Youkyoung, Cho, Nariya, Moon, Woo Kyung, Chang, Jung Min
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Breast Cancer Society 01.04.2022; 한국유방암학회
• Subjects: Brief Communication; 일반외과학; COVID-19; Lymphadenopathy; Breast Neoplasms; Vaccination
• ISSN: 1738-6756; 2092-9900
• DOI: 10.4048/jbc.2022.25.e10

This study aimed to evaluate the imaging and pathological findings in axillary lymph nodes in patients with breast cancer who received concurrent ipsilateral coronavirus disease 2019 (COVID-19) vaccination. Of the 19 women with breast cancer who received concurrent COVID-19 vaccination shot in the arm ipsilateral to breast cancer, axillary lymphadenopathy was observed in 84.2% (16 of 19) of patients on ultrasound (US) and 71.4% (10 of 14) of patients on magnetic resonance imaging (MRI), and 21.0% (4 of 19) of patients were diagnosed with metastasis. Abnormal US and MRI findings of cortical thickening, effacement of the fatty hilum, round shape, and asymmetry in the number or size relative to the contralateral side were noted in more than half of the non-metastatic and metastatic lymph nodes; however, statistical significance was not noted. Axillary lymphadenopathy is commonly observed in patients with breast cancer who receive concurrent ipsilateral COVID-19 vaccination without specific differential imaging features. Thus, understanding the limitations of axillary imaging and cautious interpretation is necessary to avoid overestimation or underestimation of the axillary disease burden.